Global quantitative proteomics of cells treated with the immunomodulatory drug pomalidomide or dipeptide degrons; global quantitative proteomics of cells treated with heterobifunctional degraders embedded with thalidomide or cyclic imide degrons; gloabl quantitative proteomics of red blood cells to search for the presence of C-terminal cyclic imide modifications on hemoglobin.